Great sleuthing there. This will be untrue once Ryoncil gets past the line. Physicians and parents will have something they've been waiting for so many years.
Despite the setback, RBC Capital Markets analyst Brian Abrahams still believes Jakafi will eventually get its approval. Feedback from experts has been positive, “with physicians noting limited alternatives and clear signs of efficacy for the drug,” he wrote in a Wednesday note to clients. He projects the indication could get Jakafi over $300 million in U.S. peak sales.
Cell Therapy News/Articles, page-9528
-
- There are more pages in this discussion • 8,262 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |